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Introduction: Extrapulmonary small-cell carcinoma (EPSCC) is a 
rare disease. Management is based on small-cell lung carcinoma. 
Prophylactic cranial irradiation (PCI) is not routinely administered 
in EPSCC. This study investigates the role of PCI in EPSCC, by ana-
lyzing the incidence, treatment, and survival of patients with brain 
metastases in a national cohort. Disease biology and epidemiology 
are also investigated.
Methods: Patients diagnosed with primary EPSCC from the 
National Cancer Registry of Ireland from 1995 to 2007 were identi-
fied. The number of patients who developed brain metastases, their 
survival, and treatment data were documented. Patients who received 
PCI were investigated. Patient and disease characteristics, treatment, 
and survival data were stratified by stage and primary site.
Results: Two hundred eighty patients were identified; 141 (50.4%) 
were men and 139 (49.6%) were women. One hundred eighty 
six patients (66.4%) had extensive-stage disease, 65 (23.2%) had 
limited-stage disease, and in 29 patients (10.3%) the stage was 
unknown. Eighteen patients (6.4%) developed brain metastases, with 
a median overall survival of 10.1 months. Eleven (61%) received 
cranial irradiation, and 12 (67%) received palliative chemotherapy. 
Two patients in the entire cohort (0.17%) received PCI. The most 
common primary sites included the esophagus (n = 43; 15.4%), cer-
vix uteri (n = 17; 6.0%), bladder (n = 13; 4.6%), and prostate (n 
= 10; 3.6%). Median overall survival was 15.2 months (10.2–20.6) 
for limited-stage disease, 2.3 months (1.7–3.1) for extensive-stage 
EPSCC, and 3.7 months (1.3–8.3) for disease of unknown stage.
Conclusion: Brain metastases were uncommon in EPSCC compared 
with small-cell lung carcinoma. PCI is thus probably not warranted 
in this disease.
Key Words: Extrapulmonary small cell, Prophylactic cranial 
irradiation.
(J Thorac Oncol. 2013;8: 1215-1221)
Small-cell carcinomas (SCLCs) are a subset of neuroen-docrine tumors with poor differentiation, elevated mitotic 
rate, and a high proliferation index.1 These cancers are bio-
logically aggressive, disseminate early, and have a poor over-
all prognosis. SCLCs most commonly originate in the lung. 
Between 10 and 14% of patients with SCLC present with brain 
metastases at diagnosis, and 80% will develop brain metasta-
ses within 2 years of diagnosis.2 Prophylactic cranial irradia-
tion (PCI) reduces the morbidity and mortality associated with 
brain metastases in SCLC. Phase III studies demonstrate an 
improvement in overall survival (OS) and quality of life with 
PCI in limited-stage (LS) and extensive-stage (ES) SCLC that 
demonstrate a response to systemic chemotherapy.3–5
SCLCs that originate outside of the lung are termed 
extrapulmonary small-cell carcinomas (EPSCCs). This dis-
ease constitutes 0.1% to 0.4% of cancers in the United States 
per year, and 2.5% to 4% of all SCLCs.6 Management of 
EPSCC is modeled on SCLC, as no prospective data exist for 
this uncommon disease.7 However, the use of PCI is not rou-
tinely recommended. Knowledge of the biology of EPSCC is 
based on single-institution studies and case series.
This study aims to analyze the incidence, treatment, and 
survival of patients with brain metastases in a national cohort 
of EPSCC, and the current use of PCI, thereby investigating 
the possible role of PCI in this disease. Secondary aims were 
to assess patient and disease characteristics, treatment, and 
survival of all patients in one of the largest cohorts in the lit-
erature on this disease. These data would provide insights into 
the biology of EPSCC compared with that of SCLC.
MATERIALS AND METHODS
A national audit was undertaken of patients diagnosed 
with primary EPSCC from the National Cancer Registry of 
Ireland (NCRI), between 1995 and 2007. Clinical data col-
lected included: patient age, sex, smoking status, primary site, 
stage, and grade. Treatment data consisted of the number of 
patients who underwent surgery, chemotherapy, and radio-
therapy (RT), stratified by disease stage. Information on all 
registered metastatic tumors in these patients was compiled, as 
far as these data were available. Patients were classified as ES 
if site(s) of metastasis or stage IV disease was recorded. All 
other patients were classified as LS.
Chemotherapy was subclassified into postoperative, 
concurrent/sequential, or palliative. RT was subdivided into 
local treatment to the primary, local treatment to the metastasis, 
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whole-brain radiotherapy, and PCI. OS was defined as the 
time interval from histologic diagnosis to death.
Patients who developed brain metastases were identi-
fied, and their clinicopathologic features were analyzed. These 
included age, primary site, stage, metastatic sites, and OS.
Statistical Analysis
Descriptive statistics were used to summarize patient 
characteristics. OS data were estimated by the Kaplan–
Meier method, and survival curves were compared with 
the log-rank method. Cox regressional hazard model was 
used for univariate analysis to assess the effects of differ-
ent covariates on OS. Covariates that achieved statistical 
significance (p < 0.05) were entered into a multivariate Cox 




Two hundred eighty patients with a confirmed histologic 
diagnosis of EPSCC were identified. Patient characteristics 
are summarized in Table 1.
Disease and Treatment Characteristics
Disease characteristics are shown in Table 2. The most 
common primary sites were the esophagus (n = 43; 15.4%), 
cervix uteri (n = 17; 6.0%), bladder (n = 13; 4.6%), and pros-
tate (n = 10; 3.6%). At diagnosis, 186 patients (66.4%) had 
ES EPSCC, 65 (23.2%) had LS disease, and in 29 patients 
(10.3%) the stage was unknown. The most common meta-
static sites were the liver (n = 110; 34.9%), lymph nodes 
(LNs) (n = 58; 20.7%), lung (n = 38; 12.0%), and bone (n = 
36; 11.4%). Six of 65 patients with LS EPSCC had regional 
LN involvement.
Treatment
Treatment data are shown in Table 3. One hundred 
sixteen patients (41.4%) received no form of therapy. 
TABLE 1.  Patient Characteristics
Patient Characteristic n (%)
Age, yr
  Median 65
  Range 17–85
Sex
  Male 141 (50.35)
  Female 139 (49.64)
Smoker
  Current 87 (31.07)
  Ex-smoker 49 (17.50)
  Unknown 58 (20.71)
  Never smoker 86 (30.71)
The number of patients with extrapulmonary small-cell carcinoma stratified by age, 
sex, and smoking status.
TABLE 2.  Disease Characteristics
Disease Characteristic N (%)
Primary site
  Head and neck 12 (4.28)
  Cardiorespiratory
   Thorax NOS 1 (0.3)
   Mediastinum 3 (1.0)
   Trachea 4 (1.4)
  Gastrointestinal
   Esophagus (all) 43 (15.4)
   Stomach 18 (6.4)
   Colon 3 (1.0)
   Rectosigmoid 6 (2.0)
   Other 9 (3.1)
  Hepatobiliary
   Pancreas 3 (1.0)
   Ampulla of Vater 1 (0.3)
   Liver 1 (0.3)
  Genitourinary
   Cervix uteri 17 (6.0)
   Endometrium 3 (1.0)
   Other (genitalia) 6 (1.9)
   Prostate 10 (3.6)
   Bladder 13 (4.6)
   Other (urinary) 6 (2.0)
  Lymph nodes 1 (0.3)
  Unknown 110 (39.2)
  Breast 7 (2.5)
  Skin 3 (1.0)
Grade
  Well differentiated 1 (0.3)
  Moderately differentiated 5 (1.7)
  Poorly differentiated 68 (24.2)
  Undifferentiated/anaplastic 76 (27.1)
  Unknown 130 (46.4)
Sites of metastasis N (% of total)
Local Recurrence Distant Metastasis
  Total 21 316
  Head and neck 2 (9.5) 0 (0)
  Cardiorespiratory
   Lung 0 (0) 38 (12.0)
   Other 1 (4.8) 9 (2.8)
  Gastrointestinal
   Liver 0 (0) 110 (34.8)
   Esophagus 3 (14.3) 0 (0)
   Peritoneum 1 (4.8) 11 (3.5)
   Other 1 (4.8) 12 (3.8)
  Genitourinary
   Cervix uteri 5 (23.8) 1 (0.3)
   Other (genitalia) 0 (0) 3 (0.9)
   Other (urinary) 1 (4.8) 5 (1.6)
   Prostate 0 (0) 2 (0.6)
   Bladder 3 (14.3) 1 (0.3)
(Continued )
1217Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 9, September 2013 Prophylactic Cranial Irradiation in EPSCC
Fifty-four patients (19.3%) underwent surgery. One 
hundred fourteen patients (40.7%) underwent chemo-
therapy. One hundred thirty patients (46.4%) underwent 
RT. Twenty patients (7%) received concurrent/sequential 
chemo-radiotherapy.
Survival
Median OS for the entire cohort of patients with LS, ES, 
and disease of unknown stage was 15.2 months, 2.3 months, 
and 3.7 months, respectively. Median OS for patients who 
received at least one modality of treatment was 17.9, 6.6, and 
10.7 months for LS, ES, and unknown-stage EPSCC, respec-
tively (Fig. 1).
Two patients in the cohort received PCI. Both were alive 
at data cutoff, with an OS of 11.1+ months and 33.8+ months, 
respectively.
Univariate analysis identified disease stage, age, sur-
gery, chemotherapy, RT, and the presence of hepatic or 
pulmonary metastases as potential prognostic factors. In mul-
tivariate analysis, disease stage, surgery, chemotherapy, RT, 
and the presence of hepatic metastases remained independent 
prognostic factors (Table 4).
Brain Metastases in EPSCC
Eighteen patients in the cohort (6.4%) developed brain 
metastases (Fig. 2B). Ten patients (56%) were men, and eight 
(44%) were women. Twelve (67%) were current smokers. 
Sixteen (89%) of these patients had ES EPSCC at diagnosis, 
seven of whom had brain metastases at initial presentation. 
Fourteen patients (77.7%) were diagnosed and recorded as hav-
ing brain metastases after the year 2000, compared with four 
patients (22.2%) before 2000. The most common primary site 
was unknown (n = 6; 33%), followed by the esophagus (n = 3; 
17%), prostate (n = 3; 17%), cervix (n = 1; 6%), hepatobiliary 
(n = 1; 6%), gastrointestinal tract not otherwise specified (n = 
1; 6%), stomach (n = 1; 6%), ovary (n = 1; 6%), and head and 
neck (n = 1; 6%).
In terms of treatment, 16 patients received some form 
of initial therapy. Two patients (11.1%) underwent surgery, 14 
(77.7%) received chemotherapy, of whom 13 (92.9%) were 
received chemotherapy of palliative intent, and four (22.2%) 
received RT. All patients with LS EPSCC and regional LN 
involvement (n = 6) received some form of treatment, and 
none of these patients developed brain metastases. Eleven 
patients (61%) received whole-brain radiotherapy for the 
treatment of brain metastases.
The median OS of the 16 patients with brain metasta-
ses who received treatment, was 10.5 months, compared with 
10.4 months for all treated patients with no evidence of brain 
metastases (hazard ratio 1.27; 95% CI 0.72–2.35; p = 0.378) 
(Fig. 2). For the two untreated patients with brain metastases, 
OS was 0.5 and 0.6 months, respectively.
TABLE 2. (Continued )
Disease Characteristic N (%)
  Lymph nodes 2 (9.5) 58 (18.4)
  Skin 0 (0) 7 (2.2)
  Bone 0 (0) 36 (11.4)
  Connective tissue 0 (0) 2 (0.6)
  Brain 0 (0) 18 (5.7)
This table summarizes the number of patients with extrapulmonary small-cell 
carcinoma stratified by site of primary disease, histopathologic grade, and sites of 
metastasis, classified as either a local or distant recurrence.
NOS, not otherwise specified.
TABLE 3.  Treatment Data
Treatment Characteristic
N (% of Total Patients) Patient No. (% of Treated Patients)
Total Limited Stage Extensive Stage Unknown
Surgery 54 (19.3) 28 (51.9) 26 (48.1) 1 (1.9)
Chemotherapy
  All 114 (40.7) 36 (31.6) 71 (62.3) 7 (6.1)
  Postoperative 17 (6.1) 8 (47.0) 8 (47.0) 1 (5.9)
  Concurrent/sequential chemo-radiotherapy 20 (7.1) 12 (60.0) 6 (30.0) 2 (10.0)
  Palliative 77 (27.5) 16 (20.8) 57 (74.0) 4 (5.2)
Radiotherapy a
  All 130 (46.4) 33 (25.4) 91 (70.0) 6 (4.6)
  Local to primary 66 (23.6) 33 (50.0) 27 (40.9) 6 (9.0)
  Local to metastasis 44 (15.7) 0 (0) 44 (100) 0 (0)
  Whole-brain 11 (3.9) 0 (0) 11 (100) 0 (0)
  Unknown 9 (3.2) 0 (0) 9 (100) 0 (0)
Prophylactic cranial irradiationb 2 (0.71) 0 (0) 2 (100) 0 (0)
This table indicates the total number of patients with EPSCC who underwent surgery, chemotherapy, radiotherapy, and prophylactic cranial irradiation. Patients are stratified 
according to stage of disease.
aRadiotherapy includes first, second, and third sites of radiotherapy.
bProphylactic cranial irradiation refers to treatment for patients who received brain radiotherapy without documented whole-brain metastases.
EPSCC, extrapulmonary small-cell carcinoma.
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DISCUSSION
EPSCC is an uncommon malignancy. In the 12-year 
period during which 280 cases of EPSCC were recorded by 
the NCRI, 3028 cases of SCLC were recorded. Prospective 
data on EPSCC would thus be difficult and time consuming 
to obtain.
To our knowledge, this is the largest data set on EPSCC, 
which examines the incidence and management of brain 
metastases. This study demonstrates a low incidence of brain 
metastases (6.4%) that is comparable with the incidence in 
published studies (4.1%–13%).8–10 Two patients in our cohort 
underwent PCI as part of initial management. Only 2.5% 
of the entire patient cohort presented with brain metastases 
at initial diagnosis, a much lower incidence compared with 
SCLC.2 This would suggest that the natural history of EPSCC 
differs from that of SCLC with respect to the development of 
brain metastases.
The median survival data for both LS and ES EPSCC 
in this cohort are poor compared with that in published 
studies7,8.11 However, 41.4% of our cohort received no treat-
ment at all, and only 40.7% received any chemotherapy. 
The OS data in this study are derived from a population-
based registry with a larger sample size, and is compara-
ble to larger provincewide data.12 The survival data in this 
study might therefore represent more realistic outcomes in 
ESPCC. However, all patients who developed brain metas-
tases received some form of therapy. The low incidence of 
brain metastases can thus be explained by a lack of receipt 
of standard therapy by a large proportion of the cohort, 
resulting in poor OS, and an inability to live long enough to 
develop brain metastases.
Differences between SCLC and EPSCC in terms of dis-
ease biology and pattern of metastatic spread constitute the 
subject of ongoing debate. In LS SCLC, regional LN involve-
ment is common and is linked to the development of brain 
metastases.13
The LS EPSCC subset in this study demonstrated a 
low rate of regional LN involvement, and no development 
of brain metastases. Moreover, 33.3% (n = 6), 27.7% (n = 
5), and 5.5% (n = 1) of patients with brain metastases had 
EPSCC of gastrointestinal, genitourinary, and hepatobili-
ary origin, respectively. Metastasis of these primary tumor 
sites to brain occurs in less than 4% of cases, and could also 
account for the overall low incidence of brain metastases in 
this cohort.14
In terms of diagnosis, most cases of brain metastases 
in this cohort were diagnosed after the year 2000. We postu-
late that this could be related to increased access and use of 
advanced imaging modalities. However, registry records are 
insufficient to confirm this assertion.
A large proportion of patients in this study underwent 
surgical treatment for a disease that is classically treated with 
chemo-radiotherapy or chemotherapy alone. A minority of 
patients with SCLC would be amenable to surgery. This could 
suggest a biological difference between SCLC and EPSCC, 
which impacts optimal management. This is in keeping with 
a previously published study on EPSCC treatment in the 
Surveillance Epidemiology and End Results (SEER) database.15
It is also noted that in a significant proportion of patients 
in this cohort, the stage of disease was unknown. The median 
OS for this group of patients was poor, suggesting the pos-
sibility that these cases could have represented unconfirmed 
ES SCLC.
In terms of the risk factors for EPSCC, 66.7% of the 
patients (n = 12) who developed brain metastases were cur-
rent smokers. However, only 31% (n = 87) of the entire 
cohort represented current smokers, and 20% (n = 58) did 
not have their smoking status recorded. Possible genomic 
abnormalities in smokers compared with nonsmokers could 
account for these findings, and require further study. This is 
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The most common sites of disease for EPSCC were 
the esophagus, cervix, bladder, and prostate. Three of these 
four sites are hollow visci that are prone to local inflam-
mation, infections, and reflux conditions. No data could be 
found in the literature regarding possible etiological fac-
tors of EPSCC. These observations can thus be considered 
hypothesis-generating.
This study highlights the importance of a national 
cancer database, particularly to provide insights into the 
incidence and behavior of rare cancers. A possible limi-
tation of our study, which applies to all registry-based 
studies, concerns data completeness. However, the NCRI 
has a 97% estimation of data completeness for pri-
mary registration. Also, in relation to the pathological 
classification of tumor grade, SCLCs are poorly differen-
tiated or undifferentiated carcinomas. Six patients were 
classified as well or moderately differentiated, and in 
130 cases histologic grade was not recorded. As this data 
set spans a 12-year period, older data could have been 
misclassified.
There are currently no guidelines that recommend the 
routine use of PCI in EPSCC. This is the largest data set 
aimed at investigating this clinical question. These data do 
not support PCI in the treatment of EPSCC because of a low 
incidence of brain metastases and possible fundamental dif-
ferences in disease biology and metastatic spread between 
EPSCC and SCLC.
TABLE 4.   Univariate and Multivariate Analyses of Patient and Treatment Characteristics
Variable
Univariate Analysis Multivariate Analysis
HR 95% CI p HR 95% CI p
Stage
  Limited 1 1
  Extensive 2.81 2.05–3.92 <0.001 1.93 1.36–2.77 0.0002
  Unknown 2.45 1.49–3.92 0.0006 1.53 0.91–2.50 0.1064
Sex
  Male 0.95 0.74–1.22 0.6891
  Female
Smoking
  Current 1
  Ex 0.78 0.54–1.14 0.1997
  Never 1.11 0.80–1.52 0.5403
  Unknown 0.65 0.47–0.93 0.0196
Age (yr)
  <65 0.61 0.47–0.78 0.0001 0.84 0.51–1.15 0.4538
  ≥65
Surgery
  Yes 0.37 0.26–0.51 <0.0001 0.39 0.26–0.58 <0.0001
  No
Chemotherapy
  Yes 0.45 0.35–0.58 <0.0001 0.47 0.34–0.64 <0.0001
  No
Radiotherapy
  Yes 0.43 0.33–0.56 <0.0001 0.5 0.37–0.66 <0.0001
  No
Brain metastases
  Yes 0.88 0.52–1.39 0.5957
  No
Hepatic metastases
  Yes 2.21 1.70–2.87 <0.0001 1.48 1.10–1.92 0.0088
  No
Pulmonary metastases
  Yes 1.45 1.03–1.99 0.0334 1.38 0.97–1.92 0.0732
  No
This table indicates the hazard ratios, confidence intervals, and p values by univariate analysis, for disease stage, sex, smoking status, age, presence of brain, hepatic, and pulmonary 
metastases. Hazard ratios, confidence intervals, and p values by univariate analysis are tabulated for treatment characteristics including surgery, chemotherapy, and radiotherapy. 
Subsequent multivariate analysis for characteristics with a statistically significant univariate analysis, are included.
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